Market Cap 617.78B
Revenue (ttm) 94.19B
Net Income (ttm) 26.80B
EPS (ttm) N/A
PE Ratio 23.56
Forward PE 21.88
Profit Margin 28.46%
Debt to Equity Ratio 0.44
Volume 6,782,000
Avg Vol 8,338,336
Day's Range N/A - N/A
Shares Out 2.41B
Stochastic %K 37%
Beta 0.24
Analysts Strong Sell
Price Target $273.67

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospit...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 732 524 0400
Website: www.jnj.com
Address:
One Johnson & Johnson Plaza, New Brunswick, United States
EWavePlayer
EWavePlayer Aug. 3 at 4:44 PM
$LABU More and more companies will be adopting the AI technology for maximum productivity and efficiency. Biotech and robotics come to mind- in being first to benefit the most. $IBB $JNJ $MRK $TSLA
0 · Reply
DidYouReadThis
DidYouReadThis Aug. 3 at 4:05 PM
0 · Reply
KarenMiller249
KarenMiller249 Aug. 3 at 3:03 PM
$JNJ $MA $CSCO $INTC $BAC Johnson & Johnson offers defensive healthcare exposure, Mastercard leads payment networks, Cisco expands AI networking, Intel continues its manufacturing turnaround, and Bank of America benefits from higher financial activity.
0 · Reply
TheresaField389
TheresaField389 Aug. 3 at 2:36 PM
$JNJ $MA $CSCO $INTC $BAC Johnson & Johnson offers defensive healthcare exposure, Mastercard leads payment networks, Cisco expands AI networking, Intel continues its manufacturing turnaround, and Bank of America benefits from higher financial activity.
0 · Reply
Wallstfan
Wallstfan Aug. 3 at 1:59 PM
$JNJ added at $251 and change
0 · Reply
outlawinvestor1
outlawinvestor1 Aug. 3 at 12:18 PM
$HELP huge news for helus - major ceo upgrade! $JNJ https://ir.helus.com/news-releases/news-release-details/helus-pharma-appoints-michael-halstead-chief-executive-officer
0 · Reply
Outcomes
Outcomes Aug. 3 at 11:18 AM
$IBRX $MRNA $PFE $JNJ .......'They "think" that vaccine-related disease enhancement won't be an added risk.' THINK AGAIN! aka.....'Turbo-cancers'. mRNA BAD. PSS knows.
0 · Reply
JuggernautRaider
JuggernautRaider Aug. 3 at 12:37 AM
$BMY looking great just like $PFE $GILD and of course the venerable $JNJ ⭐️ ⭐️ ⭐️ ⭐️
0 · Reply
clan
clan Aug. 2 at 1:26 PM
$ELTP 10-K for Elite Pharma. "Recent Developments: On April 2, 2026, we announced the comercial launch of our generic methadone hydrochloride 5 mg and 10 mg tablets. 💊 The product is marketed and sold under the Elite Labs label and represents an expansion of the Elite Pharmaceuticals' generic product portfolio. On June 1, 2026, Elite filed an Abbreviated New Drug Application [ANDA] with the US Food and Drug Administration for a generic version of an undisclosed 🤔 drug product in the class of medications caled anticoagulants."[Eloquis] 😲 $TEVA $JNJ 😲 $VTRS
0 · Reply
ICEMAN_ALERT
ICEMAN_ALERT Aug. 1 at 9:51 PM
​If upcoming trial data holds, the IBD space is primed for major shifts over the next decade. $PTGX and $JNJ could dominate first-line treatment as oral IL-23s replace injectables. $SYRE stands out as a prime buyout candidate through combo therapies and strong Phase 2 data (40% remission rate), while $AGMB targets high-unmet needs in fibrostenosing Crohn's.
1 · Reply
Latest News on JNJ
Johnson & Johnson Transcript: Investor update

Aug 3, 2026, 8:00 AM EDT - 5 hours ago

Johnson & Johnson Transcript: Investor update


Johnson & Johnson lowers 2026 profit forecast

Jul 29, 2026, 5:38 PM EDT - 4 days ago

Johnson & Johnson lowers 2026 profit forecast


Explainer: Can J&J finally put the talc litigation behind it?

Jul 29, 2026, 12:01 PM EDT - 5 days ago

Explainer: Can J&J finally put the talc litigation behind it?


Johnson & Johnson agrees to pay $5.5B to settle talc lawsuits

Jul 28, 2026, 12:26 PM EDT - 6 days ago

Johnson & Johnson agrees to pay $5.5B to settle talc lawsuits


J&J offers $5.5bn to settle baby powder lawsuits

Jul 28, 2026, 12:31 AM EDT - 6 days ago

J&J offers $5.5bn to settle baby powder lawsuits


DePuy Synthes Acquires Expanding Innovations™

Jul 16, 2026, 8:00 AM EDT - 18 days ago

DePuy Synthes Acquires Expanding Innovations™


Johnson & Johnson Earnings Call Transcript: Q2 2026

Jul 15, 2026, 8:30 AM EDT - 19 days ago

Johnson & Johnson Earnings Call Transcript: Q2 2026


Johnson & Johnson Slides: Q2 2026

Jul 15, 2026, 8:30 AM EDT - 19 days ago

Johnson & Johnson Slides: Q2 2026


Johnson & Johnson Earnings release: Q2 2026

Jul 15, 2026, 8:30 AM EDT - 19 days ago

Johnson & Johnson Earnings release: Q2 2026


Johnson & Johnson Quarterly report: Q2 2026

Jul 15, 2026, 8:30 AM EDT - 19 days ago

Johnson & Johnson Quarterly report: Q2 2026


Johnson & Johnson Hikes Guidance, Stock Falls

Jul 15, 2026, 6:35 AM EDT - 19 days ago

Johnson & Johnson Hikes Guidance, Stock Falls


Johnson & Johnson Bumps Up Guidance as Sales Rise

Jul 15, 2026, 6:33 AM EDT - 19 days ago

Johnson & Johnson Bumps Up Guidance as Sales Rise


Johnson & Johnson reports Q2 2026 results, raises 2026 outlook

Jul 15, 2026, 6:20 AM EDT - 19 days ago

Johnson & Johnson reports Q2 2026 results, raises 2026 outlook


The Big 3: UNH, KO, JNJ

Jul 9, 2026, 1:00 PM EDT - 25 days ago

The Big 3: UNH, KO, JNJ

KO UNH


Johnson & Johnson to Buy Firefly Bio for $1 Billion

Jun 8, 2026, 9:01 AM EDT - 2 months ago

Johnson & Johnson to Buy Firefly Bio for $1 Billion


Johnson & Johnson to buy Firefly Bio for $1 billion

Jun 8, 2026, 8:08 AM EDT - 2 months ago

Johnson & Johnson to buy Firefly Bio for $1 billion


EWavePlayer
EWavePlayer Aug. 3 at 4:44 PM
$LABU More and more companies will be adopting the AI technology for maximum productivity and efficiency. Biotech and robotics come to mind- in being first to benefit the most. $IBB $JNJ $MRK $TSLA
0 · Reply
DidYouReadThis
DidYouReadThis Aug. 3 at 4:05 PM
0 · Reply
KarenMiller249
KarenMiller249 Aug. 3 at 3:03 PM
$JNJ $MA $CSCO $INTC $BAC Johnson & Johnson offers defensive healthcare exposure, Mastercard leads payment networks, Cisco expands AI networking, Intel continues its manufacturing turnaround, and Bank of America benefits from higher financial activity.
0 · Reply
TheresaField389
TheresaField389 Aug. 3 at 2:36 PM
$JNJ $MA $CSCO $INTC $BAC Johnson & Johnson offers defensive healthcare exposure, Mastercard leads payment networks, Cisco expands AI networking, Intel continues its manufacturing turnaround, and Bank of America benefits from higher financial activity.
0 · Reply
Wallstfan
Wallstfan Aug. 3 at 1:59 PM
$JNJ added at $251 and change
0 · Reply
outlawinvestor1
outlawinvestor1 Aug. 3 at 12:18 PM
$HELP huge news for helus - major ceo upgrade! $JNJ https://ir.helus.com/news-releases/news-release-details/helus-pharma-appoints-michael-halstead-chief-executive-officer
0 · Reply
Outcomes
Outcomes Aug. 3 at 11:18 AM
$IBRX $MRNA $PFE $JNJ .......'They "think" that vaccine-related disease enhancement won't be an added risk.' THINK AGAIN! aka.....'Turbo-cancers'. mRNA BAD. PSS knows.
0 · Reply
JuggernautRaider
JuggernautRaider Aug. 3 at 12:37 AM
$BMY looking great just like $PFE $GILD and of course the venerable $JNJ ⭐️ ⭐️ ⭐️ ⭐️
0 · Reply
clan
clan Aug. 2 at 1:26 PM
$ELTP 10-K for Elite Pharma. "Recent Developments: On April 2, 2026, we announced the comercial launch of our generic methadone hydrochloride 5 mg and 10 mg tablets. 💊 The product is marketed and sold under the Elite Labs label and represents an expansion of the Elite Pharmaceuticals' generic product portfolio. On June 1, 2026, Elite filed an Abbreviated New Drug Application [ANDA] with the US Food and Drug Administration for a generic version of an undisclosed 🤔 drug product in the class of medications caled anticoagulants."[Eloquis] 😲 $TEVA $JNJ 😲 $VTRS
0 · Reply
ICEMAN_ALERT
ICEMAN_ALERT Aug. 1 at 9:51 PM
​If upcoming trial data holds, the IBD space is primed for major shifts over the next decade. $PTGX and $JNJ could dominate first-line treatment as oral IL-23s replace injectables. $SYRE stands out as a prime buyout candidate through combo therapies and strong Phase 2 data (40% remission rate), while $AGMB targets high-unmet needs in fibrostenosing Crohn's.
1 · Reply
clan
clan Aug. 1 at 9:20 PM
$ELTP Elite has a lot going for it: - Record Revenues, - Profitable, - Building Cash reserves, - Proprietary technology, - Growing pipeline, ... Take a look ( • ) ( • ) 👀 $TEVA 👀 $JNJ 👀 $SPY 👀
0 · Reply
Cache_Money
Cache_Money Aug. 1 at 8:37 PM
Here is how the IBD landscape could evolve over the next decade, assuming strong upcoming trial data for all players listed: -$PTGX’s and $JNJ’s Icotrokinra becoming the frontline standard of care for IBD. IL-23 pathway inhibitors already have displaced TNFi’s due to unprecedented safety and an oral IL-23 will capture a large market share from injectables as we have already seen in PsO. -$SYRE ’s combo therapies step in for a significant percentage of monotherapy non-responders. The TL1A/IL-23 combo is in phase 2 already and Spyre also has a half-life extended alpha 4 beta 7 antibody with a 40% (!) clinical remission rate on its own that also has combo potential. All three targets have an excellent safety profile. Spyre is a prime buyout candidate, especially given strong phase 2 SKYLINE results in 2026 and 2027. -$AGMB’s ALK5i used in fibrostenosing Crohn’s Disease, a highly unmet medical need. Patients will remain on immune pathway inhibitors like the ones above.
0 · Reply
imjustjimmymoore
imjustjimmymoore Aug. 1 at 5:19 PM
$MRNA $IBIO $JNJ $BTC.X $XRP.X TIME TO JUMP IN THE BIOTECH SECTOR
0 · Reply
PredictionFLO1
PredictionFLO1 Aug. 1 at 5:11 PM
$JNJ by the numbers on the daily chart. Last close $256.35, up 0.2% on the session, below its 20 day average ($257.79) but still above the 50 day ($245.20), a pullback inside a larger uptrend until proven otherwise. RSI reads 52, neutral territory. The 3 month range runs $220.37 to $274.90, and the close sits 6.7% off that high. Over the last 10 sessions, 72% of the volume traded on up days, so the buying had the participation. Why volume matters next to price: a move on heavy volume had participation, a move on thin volume is easier to unwind. The same candle means different things at 0.5x and 2x average volume. The options tape adds context today: $3.2M in notable JNJ premium, 100% bullish.
0 · Reply
wyoming2020
wyoming2020 Aug. 1 at 11:10 AM
$VKTX with 1B in cash expected, a late stage pipeline, seems a very nice setup for a cash and stock merger, low-risk for a buyer here. An $ABBV or $JNJ could pick this up by sneezing
5 · Reply
RayWashburn860
RayWashburn860 Aug. 1 at 5:11 AM
$JNJ Johnson & Johnson remains one of the highest-quality healthcare companies, supported by diversified pharmaceutical and medical technology businesses. Strong cash generation and defensive characteristics make it attractive during uncertain markets.
0 · Reply
BioTechHealthX
BioTechHealthX Aug. 1 at 3:55 AM
$JNJ Johnson & Johnson reported $25.31 billion in quarterly sales, stronger earnings and a higher full-year forecast. Discover why JNJ stock remains one of the most durable healthcare investments to watch. https://biotechhealthx.com/biotech-news/could-johnson-johnson-jnj-be-the-reliable-healthcare-investment-your-portfolio-needs/
0 · Reply
clan
clan Aug. 1 at 12:47 AM
$ELTP 2 weeks 'til next Earnings Call for Elite Pharma. Heading up. A share price spike ... UP. 🏐 ( . ) ( . ) Elite is elite! $TEVA 👀 $JNJ 💪 $NVS
0 · Reply
TraderDaKing
TraderDaKing Jul. 31 at 4:53 PM
$PFE $JNJ $LLY $MRNA Which Big Pharma is making the Deal???????
0 · Reply
G101SPM
G101SPM Jul. 31 at 4:19 PM
#SHOWTIME Ai4 Summit (August 3) Scheduled to appear: $NICE, Johnson & Johnson OTTAVA FDA Approval Call (August 3) Scheduled to appear: $JNJ Call Information Merck & Co., Inc. Business Update Call (August 3) Scheduled to appear: $MRK
0 · Reply
Redditmod
Redditmod Jul. 31 at 3:30 PM
$JNJ not bearish but these companies are monsters
0 · Reply
Mmssmm
Mmssmm Jul. 31 at 2:58 PM
$QNCX $MRK $UTHR $JNJ $LQDA QNCX NEW COVERAGE BY OPPENHEIMER Lifesci Capital LAM-001 Orphan Drug Designation by FDA ACQUISITION COMING LOW FREE FLOAT
0 · Reply